Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240035/S003

ETHIZIA Hemostatic Patch

ETHICON, Inc. · Decision date Jan 28, 2026

FDA DECISIONP240035/S003

What did the FDA approve?

FDA records P240035/S003 as a supplement to PMA P240035, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 28, 2026.

FDA approval order statement

the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240035
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
General, Plastic Surgery
Decision date
Jan 28, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240035/S003
Regulatory pathway
PMA supplement
Applicant
ETHICON, Inc.
Product code
SGV
Decision code
APPR
Decision date
Jan 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, collagen with polymeric additives.

Applicant
ETHICON, Inc.
Product code
SGV
FDA device class
3

For the original device and its historical approval scope, see PMA P240035. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240035/S003 received

    Application receipt date recorded by FDA.

  2. P240035/S001 · Related supplement

    ETHIZIA Hemostatic Patch

  3. P240035/S003 · FDA decision

    Normal 180 Day Track No User Fee

  4. P240035/S006 · Related supplement

    ETHIZIA Hemostatic Patch

  5. P240035/S005 · Related supplement

    ETHIZIA Hemostatic Patch

  6. P240035/S002 · Related supplement

    ETHIZIA Hemostatic Patch

  7. P240035/S004 · Related supplement

    ETHIZIA Hemostatic Patch

Timeline entries are records held by MedtechLedger for P240035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240035

Product / regulatory recordCompanyPathwayDecision dateSource
ETHIZIAP240035
ETHICON, Inc.PMA approvalDec 15, 2025FDA
ETHICON, Inc.PMA supplementJan 22, 2026FDA
ETHICON, Inc.PMA supplementFeb 24, 2026FDA
ETHICON, Inc.PMA supplementFeb 26, 2026FDA
ETHICON, Inc.PMA supplementJun 25, 2026FDA
ETHICON, Inc.PMA supplementAug 27, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ETHICON, Inc.

Headquarters
Not reported
Brand website
ethicon.com
FDA applicant address
1000 Rte. 202, Raritan, NJ, 08869

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records